Vizora日本語

PRISM BioLab206A東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP

PRISM BioLab FY ending Sep 2025 results

PRISM BioLab brought in ¥677.3M in revenue.

It lost about ¥114 for every ¥100 of sales at the operating level.

Revenue changed +121.6% from the prior year.

What changed from last year

FY ending Sep 2024 → FY ending Sep 2025

Revenue
+121.6%¥305.6M → ¥677.3M
Gross profit
+68.0%¥160.5M → ¥269.8M
Operating income
Loss-¥782.4M → -¥774.5M
Operating cash flow
-1078.0%¥150.1M → -¥1.47B
Free cash flow
Loss-¥61.6M → -¥1.54B

Where the money goes

FY ending Sep 2024 → FY ending Sep 2025

Where ¥100 of sales goes

For every ¥100 PRISM BioLab sells, how much goes where, and how much is kept.

FY ending Sep 2025
Cost of sales
¥60
SG&A
¥154
Operating loss
¥114
Net loss
¥123

Annual margin trends

Gross margin39.8%
FY ending Sep 2023: 71.1%71.1%FY ending Sep 2024: 52.5%52.5%FY ending Sep 2025: 39.8%39.8%FY23FY24FY25
Operating margin-114.3%
FY ending Sep 2023: -440.0%-440.0%FY ending Sep 2024: -256.0%-256.0%FY ending Sep 2025: -114.3%-114.3%FY23FY24FY25
Net margin-123.1%
FY ending Sep 2023: -466.6%-466.6%FY ending Sep 2024: -343.4%-343.4%FY ending Sep 2025: -123.1%-123.1%FY23FY24FY25

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (2)

  • EDINET (FSA Japan)

    有価証券報告書－第14期(2024/10/01－2025/09/30)

    ID S100XCIN2025-12-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第13期(2023/10/01－2024/09/30)

    ID S100V11F2024-12-27Open

Extracted from XBRL: 36 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image